A Year After US FDA Public Hearing: CBD Demand Soars Along With Need For Safety Data

US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.

Conceptual image of CBD legalization and use.

A year after the US Food and Drug Administration’s first-ever public hearing on cannabidiols, a research collaborative warns that a public health risk is growing as demand soars with clinical data still needed for agency guidance on using the ingredients in non-drug products.

The Collaborative for CBD Science and Safety says since 2016, investment in cannabis research has increased 65%, from $115m to...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Cannabis/CBD

Baby Wipes From Firms In China, Vietnam On US Import Alert; Another Warning On Delta-8 THC

 

Warning letters to SuXiang Medical Instrument in China and Yahon Enterprise in Vietnam among recent warnings FDAS sent to OTC drug and supplement manufacturers, including a Florida firm, White Label Leaf, warned about selling gummies containing delta-8 THC, and other OTC skin care product firms.

Chevron Deference Muted, Higher Volume Ahead For US Supplement Market Regulatory Questions

 

Attorneys discuss potential impacts on consumer health products industry from Supreme Court’s “Loper Bright” decision in June on litigation brought by two fisheries, Loper Bright v. Raimondo and Relentless v. Department of Commerce.

US Warning Letter Summer Rerun: Delta-8 In Food Packaged Like Brands Popular With Children

 

Noting similar warnings a year ago, the FDA and FTC announce warnings to six more, part of a joint effort to stop sales of copycat food products containing delta-8 THC, saying companies selling these "illegal products are demonstrating complete neglect for consumer safety.”

FDA Request For Help On Hemp Regulation Gets Lower Profile In House Appropriators' Report

 

Committee’s report published with FY2025 appropriation states a different approach to establishing FDA regulation of non-drug products containing hemp as a derivative of cannabis de-scheduled as controlled substance in the US since 2018.

More from Ingredients & Safety

Oxy Marks 50th Anniversary With Line Extensions, Redesigned Packages And Acne Renamed ‘Ne’

 

Mentholatum says two line extensions made with 2% salicylic acid and its "Oxy for Every Kind of Ne" campaign reinforce the brand’s “commitment to tackling every type of acne—from face-ne and chin-ne to body-ne.”

Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

 

David Ball moves from Bayer’s North America business to be Perrigo’s first chief brand and digital officer. He joins CEO who also moved to Perrigo from Bayer with decades of branded product experience.

'Planting Trees Whose Shade We’ll Never Sit In': Q&A With Fragrance Creators’ Farah Ahmed

 

The Fragrance Creators Association president and CEO discusses the group’s vision for fragrance industry stewardship and opportunities provided by AI, biotechnology and wellness trends in an exclusive Q&A with HBW Insight.